secwatch.observer — SEC 8-K summary
======================================

Issuer:     Telomir Pharmaceuticals, Inc. (TELO)
CIK:        0001971532
Form:       8-K
Filed at:   2026-03-31T23:59:59+00:00
Accession:  0001493152-26-013872
Event type: regulatory
Sentiment:  positive
Materiality: 0.25
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Telomir regains Nasdaq compliance on annual meeting requirement
---------------------------------------------------------------

- Received letter from Nasdaq on March 30, 2026 confirming compliance with Rule 5620(a).
- Compliance achieved after holding the 2025 Annual Meeting of Shareholders.
- Nasdaq has determined the matter closed.
- No further actions required from the company regarding this deficiency.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1971532/000149315226013872/0001493152-26-013872-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1971532/000149315226013872/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-013872

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer